NanoGroup S.A. Logo

NanoGroup S.A.

ISIN: PLNNGRP00011 | Ticker: NNG | LEI: 259400HXWEAZUWRLY648
Sector: Health CareSub-Industry: Biotechnology
Country: Poland

About NanoGroup S.A.

Company Description

Mission of NanoGroup is to build a cluster of medical and biotechnological companies active in the field of diagnostics, therapy and rehabilitation of oncological patients.

Currently, the group is managing five technologically advanced nanoengineering projects organized under three specialized startups.

NanoGroup plans to sell licenses to its early-stage solutions (pre-clinical and clinical phase 1st) to international biotech companies and pharmaceutical companies.

Year founded

2013

Served area

Worldwide

Headquarters

Rakowiecka 36, 02-532 Warszawa – Poland

Financial statements

Download as Excel
Line item in (pln) 02.01.2021 01.01.2022 01.01.2023
Assets N/A 20,301,901.00 19,198,782.00
Noncurrent Assets N/A 15,217,633.00 16,269,092.00
Property Plant And Equipment N/A 432,149.00 295,513.00
Goodwill N/A 0.00 0.00
Intangible Assets Other Than Goodwill N/A 14,426,466.00 15,785,749.00
Other Noncurrent Financial Assets N/A 25,146.00 37,965.00
Current Assets N/A 5,084,268.00 2,929,690.00
Inventories N/A 48,350.00 46,478.00
Current Trade Receivables N/A 523,738.00 57,785.00
Cash and cash equivalents 9,774,533.00 3,999,486.00 2,470,927.00
Equity And Liabilities N/A 20,301,901.00 19,198,782.00
Equity 18,767,076.00 8,365,709.00 7,783,019.00
Issued Capital N/A 16,747,883.00 16,747,883.00
Retained Earnings N/A -26,232,328.00 -30,320,012.00
Retained Earnings Profit Loss For Reporting Period N/A -10,005,432.00 -838,592.00
Retained Earnings Excluding Profit Loss For Reporting Period N/A -16,226,896.00 -29,481,420.00
Share Premium N/A 29,350,927.00 29,350,927.00
Reserve Of Sharebased Payments N/A 380,664.00 3,818,606.00
Equity Attributable To Owners Of Parent N/A 7,733,812.00 7,084,070.00
Noncontrolling Interests N/A 631,897.00 698,949.00
Liabilities N/A 11,936,192.00 11,415,763.00
Noncurrent Liabilities N/A 7,431,696.00 9,991,757.00
Noncurrent Government Grants N/A 7,290,468.00 9,991,757.00
Deferred Tax Liabilities N/A 2,056.00 0.00
Current Liabilities N/A 4,504,496.00 1,424,006.00
Trade And Other Current Payables To Trade Suppliers N/A 280,222.00 202,674.00
Current Tax Liabilities Current N/A 123,736.00 155,203.00
Line item in (pln) 01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 492,492.00 139,549.00
Other Income 80,715.00 4,180,281.00
Raw Materials And Consumables Used 185,896.00 95,784.00
Services Expense 1,721,144.00 1,746,154.00
Employee Benefits Expense 1,625,133.00 2,285,236.00
Depreciation And Amortisation Expense 64,348.00 62,189.00
Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 7,536,110.00 839,048.00
Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 7,536,110.00 839,048.00
Tax Expense Other Than Income Tax Expense 26,936.00 76,014.00
Profit Loss From Operating Activities -10,586,360.00 -784,595.00
Finance Income 3.00 2,455.00
Finance Costs 108,147.00 1,365.00
Profit Loss Before Tax -10,694,504.00 -783,505.00
Income Tax Expense Continuing Operations -11,965.00 -11,965.00
Profit Loss From Continuing Operations -10,682,539.00 -771,540.00
Profit Loss From Discontinued Operations 0.00 0.00
Profit (loss) -10,682,539.00 -771,540.00
Profit Loss Attributable To Owners Of Parent -10,005,432.00 -838,592.00
Profit Loss Attributable To Noncontrolling Interests -677,107.00 67,052.00
Line item in (pln) 01.01.2022 02.01.2021 01.01.2023
Profit (loss) -10,682,539.00 N/A -771,540.00
Adjustments For Reconcile Profit Loss 8,041,082.00 N/A -2,901,407.00
Adjustments For Decrease Increase In Inventories -48,350.00 N/A 1,872.00
Adjustments For Depreciation And Amortisation Expense 64,348.00 N/A 62,189.00
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 7,512,630.00 N/A -3,392,371.00
Adjustments For Provisions -108,474.00 N/A 0.00
Adjustments For Sharebased Payments 278,772.00 N/A 88,366.00
Adjustments For Losses Gains On Disposal Of Noncurrent Assets 0.00 N/A 0.00
Other Adjustments To Reconcile Profit Loss 549,833.00 N/A 19,378.00
Adjustments For Reconcile Profit Loss 8,041,082.00 N/A -2,901,407.00
Cash Flows From Used In Operations -2,653,422.00 N/A -3,684,912.00
Income Taxes Paid Refund Classified As Operating Activities 0.00 N/A 0.00
Cash Flows From Used In Operating Activities -2,653,422.00 N/A -3,684,912.00
Purchase Of Property Plant And Equipment Classified As Investing Activities 50,044.00 N/A 8,412.00
Purchase Of Intangible Assets Classified As Investing Activities 3,820,806.00 N/A 798,456.00
Cash Flows From Used In Investing Activities -3,870,850.00 N/A -806,868.00
Proceeds From Issuing Shares 1,000.00 N/A 3,349,576.00
Proceeds From Borrowings Classified As Financing Activities 0.00 N/A 0.00
Repayments Of Borrowings Classified As Financing Activities 0.00 N/A 0.00
Payments Of Lease Liabilities Classified As Financing Activities 0.00 N/A 146,146.00
Proceeds From Government Grants Classified As Financing Activities 988,184.00 N/A 158,767.00
Interest Paid Classified As Financing Activities 0.00 N/A 0.00
Cash Flows From Used In Financing Activities 749,225.00 N/A 2,963,221.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes -5,775,047.00 N/A -1,528,559.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents 0.00 N/A 0.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes -5,775,047.00 N/A -1,528,559.00
Cash and cash equivalents 3,999,486.00 9,774,533.00 2,470,927.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
POL
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

PLNNGRP00011

LEI

259400HXWEAZUWRLY648

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Warsaw Stock Exchange

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.